CureVac

CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActiveÂ® technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.

Market valuation(2017-05-02)

$1.7 B

Company Growth (employees)

Type

Private

Tübingen, DE

Founded

2000

Size (employees)

139 (est)+5%

Website

curevac.com

CureVac was founded in 2000 and is headquartered in Tübingen, DE

Key People at CureVac

Ingmar Hoerr

Chief Executive Officer

Mathias Hothum

Baord of Directors

Franz-Werner Haas

Chief Corporate Officer

Ulrike Gnad-Vogt

Acting Chief Medical Officer

Mariola Fotin-Mleczek

Acting Chief Scientific Officer

Christof Hettich

Baord of Directors

CureVac Office Locations

CureVac has an office in Tübingen

Tübingen, DE (HQ)

Paul-Ehrlich-Str. 15

CureVac Data and Metrics

Summary Metrics

Founding Date	2000
Total Funding	$387.3 m
Latest funding size	$29.5 m
Time since last funding	10 months
Investors	Bill & Melinda Gates Foundation, DH Capital, dievini Hopp Biotech Holding, OH Beteiligungen, Sigma Group, Baillie Gifford, LBBW Asset Management, Northview LifeSciences, Chartwave, Landeskreditbank Baden-Württemberg, Baden-Württembergische Versorgungsanstalt für Ärzte, Coppel Family

CureVac's latest funding round in November 2016 was reported to be $29.5 m. In total, CureVac has raised $387.3 m. CureVac's latest valuation is reported to be $1.7 b.